The NIA-AA criteria rely on biomarkers to classify individuals as either Aβ-positive or Aβ-negative, and as neurodegenerationpositive or neurodegeneration-negative [2] [3] [4] [5] . Five biomarkers are used in the NIA-AA classification. Biomarkers of fibrillary Aβ deposition include high ligand retention on amyloid-PET and low levels of Aβ 42 in the cerebrospinal fluid (CSF). The biomarkers 'cognitively normal' to describe an elderly individual who does not meet criteria for either mild cognitive impairment or dementia.
The NIA-AA preclinical AD workgroup that proposed the concept of preclinical AD operated under the assumption that the term ' AD' referred to the pathological condition and that clinical symptoms resulting from the pathological condition are not required in the definition of AD 2 . The NIA-AA staging framework for preclinical AD 2 is based on biomarker combinations and cognition: stage 1 refers to amyloidosis without neurodegeneration (A + N -), stage 2 refers to amyloidosis plus neurodegeneration (A + N + ) and stage 3 refers to amyloidosis plus neurodegeneration (A + N + ) plus subtle cognitive deficit(s)
In the study in which SNAP was first described, 450 clinically normal individuals aged >70 years were classified using amyloid plaque density assessed by PET, brain metabolism assessed by 18 F-FDG-PET and hippocampal volume assessed by MRI 1 (see Supplementary information S1 (table) ). Of this sample, 31% of participants were at NIA-AA preclinical AD stages 1-3; 43% had neither amyloidosis nor neurodegen eration (A -N -) and were classified as being at stage 0 (REF. 1 ). 23% of participants had neuro degeneration without amyloidosis (A -N + ). The term SNAP was used to convey the notion that the latter group did not represent preclinical AD, but rather had biomarker evidence of non-AD neuro degenerative processes 1 (FIG. 2) . The proportion of APOE*ε4 carriers in the SNAP group was 13%, much lower than that in individuals with preclinical AD (~40%), and half that in individuals at stage 0 (24%). This observation supported the view that SNAP was not simply the result of measurement or classification errors, but rather had a biological basis.
Controversies followed the publication of the SNAP concept 1, 7 . In this article, we discuss the available data supporting the concept of SNAP, the course of cognitive decline in individuals with SNAP, pathophysiological basis of SNAP, as well as the controversies in the field.
of AD-related neurodegeneration include high levels of tau in the CSF, signature topographic patterns characteristic of AD-associated brain hypometabolism as assessed by 18 F-FDG-PET, and atrophy as assessed by structural MRI 5, 6 (FIG . 1) . The NIA-AA classification also introduced a new concept of preclinical AD, in which clinically normal individuals with biomarker evidence of AD pathology were hypothesized to be on the trajectory towards symptomatic AD 2 . Of note, cognitive performance inevitably declines with ageing; thus, the definition of what constitutes 'normal' cognitive performance in the context of an ageing population is not straightforward. In this article, we therefore use the term 'clinically normal' rather than Abstract | Suspected non-Alzheimer disease pathophysiology (SNAP) is a biomarker-based concept that applies to individuals with normal levels of amyloid-β biomarkers in the brain, but in whom biomarkers of neurodegeneration are abnormal. The term SNAP has been applied to clinically normal individuals (who do not meet criteria for either mild cognitive impairment or dementia) and to individuals with mild cognitive impairment, but is applicable to any amyloidnegative, neurodegeneration-positive individual regardless of clinical status, except when the pathology underlying neurodegeneration can be reliably inferred from the clinical presentation. SNAP is present in ~23% of clinically normal individuals aged >65 years and in ~25% of mildly cognitively impaired individuals. APOE*ε4 is underrepresented in individuals with SNAP compared with amyloid-positive individuals. Clinically normal and mildly impaired individuals with SNAP have worse clinical and/or cognitive outcomes than individuals with normal levels of neurodegeneration and amyloid-β biomarkers. In this Perspectives article, we describe the available data on SNAP and address topical controversies in the field. Studies in which imaging was used to classify clinically normal individuals into different biomarker-based groups indicated that men are more likely to have SNAP than women, which does not seem to be the case when CSF is used for classification into amyloid pathology and neurodegeneration categories (see Supplementary information S1 (table)). Individuals with SNAP also tend to be older than those at preclinical AD biomarkers. Different methods were used to classify the participants in these studies (see Supplementary information S1 (table)). Some studies used imaging alone 1, [8] [9] [10] [11] , others CSF biomarkers alone [12] [13] [14] , others CSF biomarkers combined with imaging 15 . . These observations are logical given that APOE*ε4 is a major risk factor for Aβ pathology 16, 17 . Clinical and imaging features of cerebrovascular disease and Lewy body disease 18 were assessed among 430 clinically normal individuals classified in preclinical AD and SNAP categories 19 . Some of these features were more prevalent in individuals with SNAP than in A -N -individuals, but were not different between individuals with SNAP and A + N + individuals. These results could be interpreted to indicate that neither subclinical cerebrovascular disease nor Lewy body disease are likely to be the substrates of the neurodegeneration observed in SNAP; however, the fact that these features were more prevalent in the SNAP than in the A -N -group argues against this conclusion. An alternative interpretation would attribute the findings to age differences among biomarker groups. The frequency of cerebrovascular disease and Lewy body disease increases with ageing and individuals with SNAP were older than A -N -individuals, but had about the same age as A + N + individuals. One study that examined the changes in the frequency of biomarker-based groups with age 20 found that the frequency of SNAP was 0 in the 50-60 years age range and then increased monotonically, reaching 24% by 89 years of age. Therefore, the frequency of SNAP in the population is not static, but increases with ageing after age 60 years.
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The characteristics of clinically normal individuals aged >70 years who were documented to become newly amyloidpositive by serial imaging of amyloid plaques by PET were assessed 21 . 42% of the individuals who met the criteria of incident amyloid positivity had SNAP at baseline and later transitioned to A + N + . As SNAP represents one or more of the non-AD processes that are common in the elderly, the researchers concluded that frequently finding elderly individuals with SNAP at baseline who later develop evidence of Aβ pathology entirely logical 21 . As Aβ accumulates slowly (over decades) [22] [23] [24] , individuals with SNAP who became Aβ-positive over a short interval undoubtedly had Aβ values close to the threshold of detection at baseline.
Cognitively impaired individuals
SNAP is a biomarker-based concept that is independent of any particular level of cognitive impairment. As in the studies of clinically normal individuals, studies of individuals with mild cognitive impairment (MCI) used several different classification methods (Supplementary information S1 (table) ). The proportions of individuals with SNAP within the MCI group reported in these studies were more variable than those reported within clinically normal individuals. This difference is likely to be due to several factors, including smaller sample sizes, differences in recruitment methods -and hence the characteristics of participants in the different study populations -and the inherent heterogeneity of MCI. SNAP was found in 17% of participants in the Alzheimer disease Disease Neuroimaging Initiative 25 , 17% of those in the study by Caroli et al. 26 , 20% of those in the study by Prestia et al. 27 , 29% of those in the study by Vos et al. 28 , 29% of those in the Mayo Clinic Study of Ageing 25 , and 35% of those in the study by Duara et al. 29 In the Alzheimer disease Disease Neuroimaging Initiative 30 , 7% of participants who were clinically diagnosed as having AD dementia met the criteria of SNAP.
The rates of clinical progression to dementia among individuals with MCI and SNAP have been assessed, with average follow-up times ranging from 1 to 2.5 years in different cohorts (see Supplementary information S1 (table)). In the study by Prestia et al. -individuals with MCI and, therefore, to a lack of power to accurately determine the outcomes of these individuals. Nonetheless, the differences in outcomes observed when the results of the studies are Thresholds and cut-off points All individuals that took part in the studies discussed above were classified categorically regarding to their positive or negative status for Aβ and neurodegeneration. However, we should note that no uniform agreement exists in the field about how to perform these measurements, nor is there agreement on numeric cut-off points denoting normal and abnormal values 34 . In fact, the precise methods for classifying individuals according to these biomarker characteristics vary considerably among studies from different centres (see Supplementary information S1 (table)). Different assays or platforms used for CSF analyses give different absolute values 35, 36 . Similarly, the output of quantitative image analyses is heavily dependent on the implementation of image processing pipelines 6 . Attempts to standardize imaging and CSF measurements are underway 35 40 . In the studies by Vos et al. 12, 28 , some clinically normal individuals and some individuals with MCI who progressed to clinical AD dementia had indeed CSF Aβ levels very close to the CSF Aβ cut-off point that define the presence of amyloidosis.
Pathological basis of SNAP
In addition to AD 41, 42 , non-AD pathologies are common with advancing age in impaired and clinically normal elderly people [42] [43] [44] [45] [46] . These pathologies include cerebrovascular disease, α-synucleinopathy, argyrophilic grain disease, TDP-43 proteinopathy and hippocampal sclerosis. Ageing alone (that is, the passage of time) is implicated in brain atrophy and cognitive decline, which probably develop as a result of synapse loss 47, 48 . Medial temporal tau pathology without amyloidosis might be a major constituent of SNAP 49, 50 . The term primary age-related aggregated suggest that a slightly different mix of underlying aetiologies might be present in patients with MCI and SNAP than those present in clinically normal individuals with SNAP.
The number of individuals with MCI and SNAP who progress to what is clinically labelled 'probable or possible AD dementia' might seem unusually high as SNAP is a non-AD state. However, two potentially confounding factors must be considered. The first is the frequency of clinical misdiagnosis of AD dementia. Up to a third of APOE*ε4 non-carrier individuals clinically diagnosed as having AD dementia by experts are amyloidosis-negative according to PET scans 33 , and thus their dementia is likely to result from pathologies other than AD. Given that APOE*ε4 carriers are underrepresented in the SNAP group relative to the A + N -and A + N + MCI groups, some patients who progressed from having SNAP and MCI to 'probable or possible AD dementia' actually had non-AD aetiologies. The second factor is that the levels of Aβ in individuals who progress from having MCI and SNAP to clinical AD dementia are more likely to have been very close to the threshold of abnormality at baseline and, therefore, these individuals were more similar to A + N + individuals than to the rest of the SNAP group 28 . tauopathy (PART) has been proposed by Crary et al. 51 to describe this phenomenon, although not without controversy 7, 52, 53 . Autopsy studies indicate that medial temporal tau pathology (often without amyloidosis, particularly at young ages) is present in 25% of the population by age 25 years, 50% by age 50 years, and in most individuals aged >75 years 49, 50, 54, 55 . Therefore, PART has been argued to be an ageing process separate from AD, the latter requiring amyloidosis 51, [56] [57] [58] . As pointed out by Crary et al. 51 , SNAP and PART share some highly salient features: both are common in clinically normal elderly people; APOE*ε4 is underrepresented in both; both increase in prevalence with ageing; and medial temporal lobe pathology features prominently in both. The first autopsy studies in individuals classified antemortem as having SNAP were performed at Washington University 12 . Three of the four individuals with SNAP who were studied had low probability of having AD and the fourth did not have AD 58, 59 . Medial temporal tau pathology without amyloidosis (that is, meeting the criteria of PART 51 ) was detected postmortem in two of the four individuals. More recent autopsy data from the Mayo Clinic also indicates that individuals in whom imaging findings meet the criteria of a SNAP diagnosis in life uniformly have non-AD diagnoses at autopsy 60 . In summary, a variety of non-AD processes are likely to contribute to neurodegeneration in individuals who meet the criteria of SNAP. Developmental factors might also play a part. This lack of specificity could be interpreted as undermining the utility of the SNAP concept; however, many examples of useful constructs with different aetiologies exist in medicine and biology. For example, neurodegeneration is a pathologic condition and MCI and dementia are clinical conditions with many aetiologies.
Defining a non-AD aetiology
The biomarkers of neurodegeneration that are characteristic of AD -medial temporal lobe atrophy assessed by MRI, hypometabolism in temporal-parietal regions assessed by 18 F-FDG-PET, and abnormally elevated levels of total tau in CSF -also define SNAP. Total tau is a nonspecific marker of neuronal injury and neurodegeneration, which is elevated in AD, whereas phosphorylated tau is specific for neurofibrillary tangle pathology of AD 61 . We recognize that this similarity might seem incongruous, but not if one views these processes as independent of Aβ.
conditions, or neither of them represent AD. Second, if preclinical A + N -is AD, whereas preclinical SNAP is not, then the likelihood of progression to more advanced stages of clinical and biomarker-defined AD should be greater for preclinical A + N -than for SNAP; however, this result was not consistently found in the different studies that examined clinical outcomes (see Supplementary information S1 (table) ). Third, the neuropathological definition of AD requires both Aβ and tau pathology 58, 59 . Therefore, both Aβ pathology and neuro degeneration should be required as biomarker evidence of AD pathophysiology. A + N -does not meet these criteria any more than SNAP. Finally, if the amyloid cascade hypothesis 76 is not correct for late-onset AD (that is, if Aβ deposition is not an upstream driver of the AD pathophysio logical cascade that leads to neurodegeneration), then labelling A + N -as preclinical AD is not more reasonable than doing so with SNAP [77] [78] [79] . The argument for defining SNAP as "suspected non-AD pathophysiology" likewise has several lines of support. First, non-AD processes are prevalent in the elderly population, as seen by autopsy studies [42] [43] [44] 51, 80 , and these processes should be evidenced by neurodegenerative biomarker abnormalities. 'Suspected non-AD pathophysiology' seems the only logical label when SNAP is due to one or more of these non-AD processes. Second, medial temporal tau pathology without excessive Aβ accumulation is explicitly defined as an ageing phenomenon separate from AD in the most recent pathological criteria for AD assessment 58, 59 and in the position paper in which the diagnostic criteria for PART are defined 51 . As PART is one of the contributing aetiologies to SNAP, labelling SNAP 'non-AD' is appropriate. Finally, if the amyloid cascade hypothesis 76 is correct (that is, if Aβ deposition drives AD-related neurodegeneration in the AD pathological cascade in early-onset and late-onset AD [81] [82] [83] ) then imaging and/or biomarker evidence of Aβ accumulation without neurodegen eration should be labelled ' AD' , whereas SNAP should be labelled "non-AD". Genetics provides strong evidence that Aβ accumulation is an upstream driver of the AD pathological cascade. Mutations that increase Aβ production or aggregation inevitably lead to clinical and pathological AD 84 in young individuals, and a mutation that decreases Aβ 42 production protects against development of clinical AD and cognitive decline in the elderly 85 . By contrast, genetically determined tauopathies do not lead to clinical or pathological AD 86 .
The patterns of atrophy and hypo metabolism in non-AD conditions often overlap spatially with the patterns seen in AD. This overlap is probably most obvious in the medial temporal lobe. Hippocampal atrophy is a prominent and early feature in typical AD 62 , but it is also a prominent feature of hippocampal sclerosis [63] [64] [65] , TDP-43 pathology 66 , argyrophilic grain disease, anoxic-ischaemic injury 67 and in ageing 48 (FIG. 4) . Temporoparietal hypometabolism is found in non-AD conditions, such as corticobasal degeneration, primary progressive aphasia 68 , and cerebrovascular disease 11 . The AD-like hypometabolism in posterior association areas that is observed in PART can be explained by the fact that these areas are highly connected, both structurally and functionally, to the medial temporal lobe [69] [70] [71] [72] . The aetiological nonspecificity of atrophy and hypometabolism observed by MRI and 18 F-FDG-PET in areas of the brain associated with AD has given rise to the concept that the brain networks in these areas can be vulnerable to a variety of insults associated with AD, non-AD disorders and ageing 47, 48, 56, 73, 74 . The same logic applies to elevated total tau levels in CSF, which are seen in conditions other than AD, including ischaemic cerebrovascular disease, traumatic brain injury, and Creutzfeldt-Jacob disease 75 .
'A' for 'amyloid' or for 'AD'? SNAP was originally coined as an abbreviation for 'suspected non-AD pathophysiology' 1 , but the term has also been referred to as an abbreviation for 'suspected non-amyloid pathophysiology' (REF. 26 ) (even if 'non-amyloid' is known, not suspected, in someone with a negative result in the Aβ biomarker analysis). These semantic differences define two important points of view. One is that biomarker evidence of Aβ pathology alone is not sufficient to define AD pathophysiology. The other perspective is that biomarker evidence of Aβ pathology alone is sufficient to define AD pathophysiology, and thus Aβ negative, neurodegeneration positive individuals (those with SNAP) should be classified as having a 'non-AD' condition. As the co-authors of this article do not unanimously agree on these points of view, we present the arguments on both sides of the issue.
The argument for defining SNAP as 'suspected non-amyloid pathophysiology' has several lines of support. First, the term 'non-amyloid' accurately reports an observation about an individual without the assumptions that A + N -, SNAP, both of these Nature Reviews | Neurology
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Whether the ' A' in SNAP stands for 'amyloid' or ' AD' is a semantic difference important to conceptual precision. How SNAP is defined also serves to define AD (and vice-versa), particularly in clinically asymptomatic individuals in whom the full pathophysiological cascade of AD has yet to play out and in whom no clinical indicators of underlying pathophysiology are present. Some researchers who believe SNAP should be included as part of the AD spectrum point to the high prevalence of clinically normal individuals with SNAP (23%) as evidence that the amyloid-centric models of AD and the concept of preclinical AD (as now defined 2, [87] [88] [89] ) are flawed. Viewed from the perspective that SNAP is not AD, however, . From this second perspective, SNAP represents biomarker evidence of the non-AD pathologies that autopsy data indicate are frequent in the elderly [42] [43] [44] . Biomarker evidence of non-AD pathologies (that is, SNAP) may or may not precede Aβ accumulation in specific individuals 21, 90 , but in either instance Aβ seems to act as a biological driver of tauopathy 23, 57, [91] [92] [93] [94] . Use of PET for detecting tau, a novel technique that, for the first time, enables in vivo determination of the anatomic distribution of tau pathology [95] [96] [97] , will shed light on this debate in the future. 
